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During the last two decades the pathological classification of
breast carcinoma has evolved rapidly. Starting from the pure
assessment of conventional morphology, it has gradually
been integrated with immunophenotypic evaluation of the
hormone receptor, HER2, and Ki67 status. In addition, molec-
ular genetic testing (mostly by fluorescence in situ hybridisa-
tion, FISH) for Her2 immunohistochemically ‘equivocal’ cases
has become a standard. Pathological evaluation of breast
specimens has shifted rapidly from a mere diagnostic pro-
cess, aimed at establishing the biological potential of a breast
‘lump’, to a far more complex integration of diagnostic, prog-
nostic and predictive parameters. The current landscape has
been further complicated by the relatively recent introduction
of a ‘molecular’ classification of breast cancer [1]. Since then
pathologists and clinicians have struggled in the attempt to
translate (or maybe to force) the classic morphological ap-
proach into a molecularly based scheme (Table 1).
Whatever the approach, the role played by the pathologist
in the clinical decision-making process has never been so
central. Establishing the correct diagnosis, as well as accu-
rately evaluating key prognostic/predictive biomarkers, repre-
sent the core of the breast cancer pathology report. Even
acknowledging the current complexity of personalised treat-
ments, it is broadly accepted that the information mandatory
for inclusion in the pathology report represents a milestone
for optimal therapeutic planning.
2. Pathological diagnosis
The pathological diagnosis of breast carcinoma still repre-
sents the key step. Before considering the complex integra-
tion of predictive and prognostic markers, it should not be
overlooked that the diagnosis of breast cancer is not always
straightforward. The presence, within the breast cancer mul-
tidisciplinary team, of a skilled breast pathologist represents
a fundamental prerequisite in order to achieve optimal thera-
peutic planning.The World Health Organisation (WHO) has recently up-
dated its breast cancer classification, separating invasive
breast carcinoma into two broad categories: invasive carci-
noma of no special type (formerly known as invasive ductal
carcinoma) and special subtypes (Table 2). The recognition
of special subtypes is relevant as distinct morphologies often
correlate with distinct clinical outcomes [2].
Once the correct diagnosis of invasive carcinoma is made,
pathologists are asked to provide a set of morphological
parameters representing important clues to prognostic strat-
ifications. These include the size of the lesion, the presence of
lymphatic and blood vessel invasion, the status of lymph
nodes and the histological grading (Table 3). The currently
adopted grading system is that devised by Elston and Ellis,
and represents a powerful prognostic tool that represents a
key factor in clinical decision-making [3]. The so-called Not-
tingham system is based on the evaluation of differentiation
(as expressed by the amount of tubule formation), nuclear
pleomorphism (by comparing neoplastic cell nuclei with adja-
cent normal breast epithelial cells) and mitotic activity (as ex-
pressed by number of mitoses counted per 10 high-power
fields). Of course the dimension of a ‘high-power field’ de-
pends on the size of the microscope. The WHO, in its most re-
cent classification, has therefore provided a conversion table
aimed at minimising inter-observer variability [2].
As shown, pathological evaluation of haematoxylin-and-
eosin-stained slides still represents the cornerstone of breast
cancer diagnosis. Even though molecular testing is playing an
increasingly key role in several fields of cancer, it is extremely
important that morphological expertise is not lost, and that
educational efforts are supported in order to maintain diag-
nostic skills to the highest possible standard.
3. Evaluation of predictive/prognostic markers
The three main biomarkers used in the routine clinical man-
agement of invasive breast carcinoma are represented by the
oestrogen receptor (ER), progesterone receptor (PR) and HER2.
More recently, the evaluation of the Ki67 labelling index has
Table 1 – Molecular classification of breast cancer.
Subtype Clinico-pathological
definition
Luminal A ER- and/or PR-positive
HER2-negative
Ki67 low (<14%)
Luminal B Luminal B (Her2-negative)
• ER- and/or PR-positive
• HER2-negative
• Ki67 high
Luminal B (Her2–positive)
• ER- and/or PR-positive
• HER2-positive
• Any Ki67
HER2-positive
(non-luminal)
HER2-positive
ER- and PR-negative
Basal-like Triple-negative (no special type)
• ER- and PR-negative
• HER2-negative
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[4]. The ER and PR play central roles in defining the hormone
responsiveness and therefore in the selection of patients for
endocrine therapy. In the past, ER expression has been vari-
ably measured; however there is a broad consensus on the
fact that immunohistochemical evaluation of ER expression
is both sensitive and specific. Immunohistochemical mea-
surement of the ER can be effectively (and relatively inexpen-
sively) performed on formalin-fixed, paraffin-embedded
(FFPE) tissue [5]. Both the proportion and the intensity of ER
expression are evaluated microscopically, with or without
the help of digital imaging tools. Approximately 80% of inva-
sive breast carcinoma variably expresses the ER. Any cut-off
of expression has been abolished as even 1% of positive cells
would still define the tumour as hormone-responsive [5]. Still,
there is a direct correlation between level of expression of the
ER and response to both tamoxifen and aromatase inhibitors
[6,7]; however, even tumours expressing extremely low levels
of ER may benefit from hormonal therapies when compared
to ER-negative ones (8).Table 2 – WHO classification of breast cancer.
Invasive carcinoma of no special type
Special types:
• Invasive lobular carcinoma
• Tubular carcinoma
• Cribriform carcinoma
• Carcinoma with medullary features
• Metaplastic carcinoma
• Carcinoma with apocrine differentiation
• Salivary gland/skin adnexal type tumours
• Adenoid cystic carcinoma
• Mucoepidermoid carcinoma
• Polymorphous carcinoma
• Mucinous carcinoma (including signet ring variant)
• Carcinoma with neuroendocrine features
• Invasive papillary carcinoma
• Invasive micropapillary carcinoma
• Inflammatory carcinoma
• Exceptional rare types and variantsThe PR is also routinely evaluated immunohistochemically
[8]. The ER regulates PR expression, and therefore the pres-
ence of the latter gives testament to the functional integrity
of the ER pathway [9]. Expression of the PR is detected in
approximately 60–70% of invasive breast cancers, and as with
the ER there is direct correlation between its level of expres-
sion and response to hormonal therapy [8,10].
The best estimation of response to hormone therapy is
generated by the combination of both ER and PR expression
[11]. The combination ER+/PR+ accounts for approximately
70% of invasive breast cancers and correlates with the best
anti-oestrogen response (60%). Approximately 25% of patients
exhibit an ER/PR phenotype which predicts unresponsive-
ness to hormone therapy. The ER+/PR cases are associated
with intermediate levels of response, whereas the very exis-
tence of true ER/PR+ cases is still the source of sharp debate.
HER2 (ERBB2) represents a proto-oncogene located on
chromosome 17 and is amplified in approximately 15% of
breast invasive carcinomas [12]. HER2 amplification strongly
correlates with protein over-expression that can therefore
be detected immunohistochemically. HER2 represents both a
prognostic and a predictive biomarker. HER2 amplification
not only correlates with poorer outcome [13] but also predicts
response to molecular targeted therapies aimed specifically
against HER2 (i.e. trastuzumab and lapatinib) [14,15]. HER2
status is primarily determined immunohistochemically on
FFPE tissue and scored according to broadly accepted guide-
lines [16]. Cases with strong complete membrane staining in
more than 30% of neoplastic cells (so-called 3+) are candi-
dates for anti-HER2 therapy. Negative or weakly positive cases
(so called 0 and 1+) are generally excluded, whereas cases
with continuous but less strong than 3+ membrane staining
undergo FISH to assess the presence of HER2 gene amplifica-
tion that, if present, would also qualify the patients for anti-
HER2 targeted therapy. The best response is seen in cases
showing strong HER2 over-expression and/or HER2 gene
amplification. Lack of accuracy in HER2 testing represents a
major obstacle to correct selection of patients and (analo-
gously to ER/PR testing inaccuracy) may impact on clinical
outcomes [17].4. Towards a molecular classification of breast
carcinoma
Molecular analysis of breast carcinoma using a gene expres-
sion array approach has led to the recognition of several
genetically distinct forms [1]. Gene expression profile assays
measure quantitatively in tumour samples the expression of
each gene harboured on the array. These techniques generate
great amounts of data that need to be analysed with bioinfor-
matic techniques. Two main approaches are most often used:
unsupervised hierarchical cluster analysis and supervised
classification. Unsupervised approaches analyse gene expres-
sion within a series of tumours without using the clinical
and/or pathological information available. Hierarchical clus-
ter analysis then subclassifies tumours into distinct sub-
groups. If the aim of analysis is to identify gene expression
patterns predictive of clinical behaviour then a supervised ap-
proach seems to be more appropriate. This technique in fact
Table 3 – The grading system of Elston and Ellis.
Morphological features Score
% Of tubule and gland formation
>75 1
10–75 2
Nuclear pleomorphism
Absent 1
Moderate 2
Mitotic count (depends on microscope field area)
Low 1
Intermediate 2
High 3
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parameters such as overall or disease-free survival as well
as response to a given therapy.
The unsupervised hierarchical cluster analysis of breast
carcinoma has led to a broad division into ER+ and ER cases
[18,19]. If the set of genes expressed by the two categories is
examined closely, ER+ cases are linked to breast luminal cells,
whereas ER cases are associated with myoepithelial cells.
The next step is the correlation of these subgroups with clin-
ical outcomes. This approach has led to the definition of the
entities (intrinsic subtypes) listed in Table 1: namely types
luminal A and B, HER2 and basal-like [1,20].
The attempt to correlate gene expression profiles with
clinical outcome has generated several gene signatures. The
most popular is represented by a 70-gene signature that
may determine prognosis in stage-1 or -2 node-negative pa-
tients affected by breast carcinomas smaller than 5 cm. The
70-gene signature separates patients into two groups with
good and poor prognoses, and appears to work as an indepen-
dent predictor of metastatic spread [1]. The 70-gene signature
has been popularised with the commercial label Mammaprint
which has been cleared by the FDA as an in vitro diagnostic
multivariate index assay.
An alternative approach is represented by the 21-gene
recurrence score [21]. This is a qRT-PCR-based signature com-
mercially named Oncotype DX, that predicts the likelihood of
recurrence at 10 years for ER-positive, lymph-node-negative
patients. The test provides a continuous recurrence score
(RS) and risk category: low (RS < 18), intermediate (RS 18–30)
and high (RS > 30). The 21-gene recurrence score apparently
may also correlate with benefit from chemotherapy in ER-po-
sitive breast cancer patients [21].
The clinical utility of gene expression profiling in breast
cancer has generated a lively and still ongoing debate. Even
if there is a strong pressure (particularly in the US, United
States) towards a broader use of such approaches, their po-
tential benefit seems until now to be restricted to a minority
of breast cancer patients. Nonetheless, also in consideration
of the rapid evolution (and cost reduction) of molecular genet-
ic techniques, it has to be expected that molecular assays will
be implemented increasingly in clinical practice.
5. Conclusions
Pathological evaluation of breast cancer specimens plays a
key role in planning the best therapeutic options. In additionto accurate diagnosis of malignancy and cancer subtype,
pathologists are central in helping clinicians in the selection
of patients for both endocrine therapy as well as for anti-
Her2 targeted approaches. Precise evaluation of breast cancer
biomarkers still represents a key issue not yet entirely re-
solved, and it has been shown to impact on clinical deci-
sion-making as well as on patient outcome. It is vital that
pathology laboratories systematically implement External
Quality Control policies aimed at achieving and maintaining
the highest diagnostic standard.
The rapid evolution of molecular techniques has in part
changed the landscape of breast cancer prognostic biomark-
ers. The advent of genomic signatures certainly represents a
step forward, but their clinical utility is being still debated;
complete agreement regarding their clinical as well as their
cost-effectiveness is still to be achieved.Conflict of interest statement
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